Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss... Show more
Hims & Hers Health has built one of the largest direct-to-consumer telehealth platforms in the U.S., with nearly 2.8 million subscribers spanning sexual health, dermatology, mental health, hormone therapy, and weight management. Its competitive advantage rests on a vertically integrated, personalized-care model that pairs telehealth providers, branded and compounded medications, and, increasingly, in-house lab testing.
The company's medium-term positioning hinges on its pivot within weight loss. After the U.S. Food and Drug Administration (FDA) declared the GLP-1 (glucagon-like peptide-1) shortage over in early 2026, the economics of compounding changed, forcing Hims to reorient toward branded therapies. Distribution agreements with Novo Nordisk and Eli Lilly give the platform access to Wegovy, Zepbound, and Foundayo, preserving its relevance in obesity care while compressing margins. In parallel, management is diversifying into peptides, testosterone, and menopause offerings, and expanding internationally to reduce reliance on any single U.S. product category.
The company's trajectory is closely tied to the broader obesity and digital-health market, where demand for GLP-1 therapies remains robust but pricing is becoming more competitive as major pharmaceutical makers expand direct-to-consumer access. Interest-rate and inflation dynamics matter through their effect on discretionary consumer spending and customer acquisition costs, which have risen on dominant advertising platforms.
Regulatory climate is arguably the most consequential macro variable. The FDA's stance on compounding and peptides directly determines which products Hims can legally and profitably offer, while evolving telehealth and subscription rules could raise compliance costs. Meanwhile, international expansion into markets such as the UK and Australia introduces currency, reimbursement, and competitive factors distinct from the U.S. model.
Investors seeking a forward-looking lens on HIMS may turn to Tickeron's Trend Prediction Engine, an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. The engine is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. It offers searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. Exploring these AI-driven signals can complement fundamental analysis when assessing a fast-evolving name like Hims & Hers.
Looking into 2026 and beyond, Hims & Hers is navigating a deliberate transition from a high-margin, single-product growth story toward a diversified, multi-market healthcare platform. Management has maintained long-term ambitions of roughly $6.5 billion in revenue and $1.3 billion in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) by 2030, but the near-term path involves compressed margins and negative operating leverage as branded drugs and international operations scale.
Key themes to monitor include whether margin sustainability improves as branded cohorts compound and retention strengthens, whether the peptide and testosterone categories deliver higher-margin growth, and whether international expansion achieves profitability without excessive acquisition and marketing costs. Competitive threats from incumbent telehealth players and direct-to-consumer offerings from pharmaceutical giants, as well as any tightening of regulatory oversight, represent the principal risks to the long-term outlook. Consensus analyst expectations remain measured, with price targets implying a wide range of outcomes that reflect both the platform's demonstrated top-line momentum and unresolved questions about its path back to sustainable profitability.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TCPB | 49.09 | 0.26 | +0.53% |
| Thrivent Core Plus Bond ETF | |||
| CPRJ | 27.13 | -0.06 | -0.22% |
| Calamos Russell 2000 Structured Alt Protection ETF July (CPRJ) | |||
| FEMV | 26.08 | -0.59 | -2.22% |
| Fidelity Enhanced Mid Cap Value ETF (FEMV) | |||
| SHDG | 31.28 | -0.72 | -2.24% |
| Soundwatch Hedged Equity ETF (SHDG) | |||
| VTHR | 304.86 | -10.82 | -3.43% |
| Vanguard Russell 3000 ETF (VTHR) | |||
A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To HIMS | 1D Price Change % | ||
|---|---|---|---|---|
| HIMS | 100% | -8.86% | ||
| COTY - HIMS | 31% Poorly correlated | -2.47% | ||
| HROW - HIMS | 29% Poorly correlated | -5.35% | ||
| AYTU - HIMS | 28% Poorly correlated | N/A | ||
| DERM - HIMS | 25% Poorly correlated | -7.04% | ||
| IRWD - HIMS | 25% Poorly correlated | -0.21% | ||
More | ||||
| Ticker / NAME | Correlation To HIMS | 1D Price Change % |
|---|---|---|
| HIMS | 100% | -8.86% |
| Pharmaceuticals: Generic industry (81 stocks) | 14% Poorly correlated | -3.61% |
| Pharmaceuticals industry (151 stocks) | 12% Poorly correlated | -3.32% |
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 66 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for HIMS entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (6.379). P/E Ratio (-41.935) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.